Exploring the Effects of Pemivibart Monoclonal Antibody Infusion in Long COVID: A Case Series Offering Initial Clinical Insights
Abstract
Long COVID, or post-COVID conditions (PCC), affects a substantial proportion of adults and is characterized by persistent symptoms such as fatigue, postexertional malaise (PEM), cognitive dysfunction, and dysautonomia. At present, no Food and Drug Administration-approved therapies exist. Pemivibart (Pemgarda), a monoclonal antibody (mAb) authorized under Emergency Use Authorization (EUA) for preexposure prophylaxis in immunocompromised individuals, has not been studied for PCC but may theoretically facilitate clearance of viral antigens. We report three individuals with longstanding, debilitating PCC who received pemivibart infusion under EUA. Each experienced rapid symptomatic improvement, most notably in fatigue with PEM, dysautonomia, and cognitive dysfunction. One patient achieved resolution of her most limiting symptoms within a week and sustained functional recovery following repeat infusion. Another demonstrated significant gains across several symptom domains and was able to resume prior physical activities, although benefits waned after two to three weeks. A third with autoimmune comorbidities reported dramatic improvement in energy and cognition, and continued to feel well at six weeks. The rationale for this case series stems from emerging hypotheses that persistent viral antigens may contribute to the pathophysiology of Long COVID and that neutralizing antibodies could facilitate antigen clearance and symptom resolution. In the three cases, pemivibart infusion…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Promising Sources of Plant-Derived Polyunsaturated Fatty Acids: A Narrative Review
- Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials
- Effect of omega-3 fatty acids on cognition: an updated systematic review of randomized clinical trials
- The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus: A narrative review
- Paucity of evidence for a relationship between long-chain omega-3 fatty acid intake and chronic obstructive pulmonary disease: a systematic review
- Omega-3 fatty acid nanocarriers: Characterization and potential applications
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.